Are there any new partnership or licensing agreements disclosed in the update?

Answer to the question

No. The corporate update for BrainStorm Cell Therapeutics (BCLI) that accompanied the Q2 2025 earnings release does not mention any new partnership, collaboration, or licensing agreements. The filing is limited to financial results, a conference‑call announcement and a brief corporate overview, with no disclosures of fresh external deals.

Trading implications

• Fundamental view: In the absence of a fresh partnership or licensing milestone—often a catalyst that can trigger a price jump—the stock’s valuation will continue to be driven by the company’s existing pipeline progress, cash‑burn rate and the broader sentiment toward adult‑stem‑cell therapeutics. Investors should focus on the Q2 operating metrics (revenue, R&D spend, cash runway) and any updates on the lead neuro‑degenerative programs when forming a price target.

• Technical view: With no new catalyst, the share price is likely to trade in a range dictated by recent earnings‑related moves. If the results beat consensus, the stock could test short‑term upside resistance around the recent high; a miss may push it toward the next support level near the 52‑week low.

Actionable insight – Until a partnership or licensing announcement surfaces, the prudent approach is to base positioning on the core fundamentals and the technical trend. Consider a neutral‑to‑light‑long stance if the Q2 results show improving cash conversion and program‑milestone momentum, but keep a tight stop just below the nearest technical support to guard against any downside that could be triggered by a lack of partnership‑driven upside.